Mylan N.V.​(MYL – Analyst Report) is one of the largest generics and specialty pharmaceutical companies in the globe. The company's product portfolio encompasses various therapeutic areas including cardiovascular, central nervous system, anti-infective, gastrointestinal, endocrine and metabolic, and respiratory drugs.

Mylan continued to launch generic drugs in the second quarter of 2015. The investor focus will remain on Mylan's deal with Perrigo.

Mylan has a mixed earnings track record with the company delivering positive earnings surprises in two of the last four quarters with an average surprise of 0.32%.

Currently, Mylan has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:

Earnings: Mylan beat on earnings in the second quarter. Our consensus called for EPS of 87 cents, and the company reported EPS of 91 cents.

Revenue: Revenues were in line with expectations. Mylan posted revenues of $2.4 billion, which was in line with our consensus estimate.

Key Stats: Both Specialty segment and Generics segment has performed well this quarter. However, foreign currency exchange translation continues to unfavorably impact revenues. Mylan also increased its earnings guidance range to guidance range to $4.15 to $4.35 as compared to previous guidance of $4.00 to $4.30 per share.

Get the latest research report on MYL – FREE